ImmVira Raises $58M in Series B Funding Round

According to VCBeat, on June 15, 2020, Immvira Group Company ("ImmVira") announced the completion of Series B financing for 58 million US dollars. Attracting some of the top international and domestic medical and biotech investors, this new round of financing was led by Huagai Capital, with participation by Apricot Capital, Cowin Capital and the lead investor from the previous round.

Proceeds from the latest round will be used for clinical researches of existing pipelines, pre-clinical development of drugs in the early stage, and the potential strategic cooperation at home and abroad.

Immvira is developing a broad range of anti-cancer therapeutic pipelines including tumor-specific target oncologic viruses by creating products of engineered oncolytic HSV (oHSV) carry single or combination of immunostimulatory or/and checkpoint blockage, which target solid tumors through local or systemic delivery in the mechanism of tumor-target lysis and tumor-killing immune responses, also developing a potent oncolytic platform suitable in combination with adjunct therapies.

On May 29, 2020, Immvira's first product, ImmVira received IND clearance of herpes simplex virus T3011 (intratumoral injection) from FDA, targeting malignant solid tumors, becoming the first onosomal virus developed in China to conduct human study in the United States, and also the first to carry out multiple-regional clinical trials in United States, Australia, and mainland China.

In addition to mono and combination therapies by T3011 (intratumoral injection), ImmVira has 4 products planned in its pipeline, covering all tumor types. Among them, T3011(systematic injection) for lung cancer and liver cancer, C5252 for malignant brain tumors, and products for virus-resistant solid tumors and hematological malignancies are also under development. More and more products will enter the clinical stage in the future.

Founded in 2012 and headquartered in Beijing, Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.

Founded in 2015, Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics.